Indeed, acquisition of a BRAF mutation in melanoma cells leads to constitutive signaling through the MAPK pathway, which in turn contributes to immune escape through the recruitment of regulatory T cells, decreased antigen presentation (via downregulation of MHC class I) and the inhibition of IFNγ, IL2, and TNFα release. This evidence concerns the gene BRAF and melanoma.